WO2004060378A2 - Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof - Google Patents
Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof Download PDFInfo
- Publication number
- WO2004060378A2 WO2004060378A2 PCT/US2003/039737 US0339737W WO2004060378A2 WO 2004060378 A2 WO2004060378 A2 WO 2004060378A2 US 0339737 W US0339737 W US 0339737W WO 2004060378 A2 WO2004060378 A2 WO 2004060378A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alumina
- particle
- particles
- functional
- article
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 253
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 title claims abstract description 158
- 150000001875 compounds Chemical class 0.000 title claims abstract description 144
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 58
- 239000000975 dye Substances 0.000 claims abstract description 97
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 73
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 36
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 31
- 230000008569 process Effects 0.000 claims abstract description 22
- 239000003205 fragrance Substances 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000007639 printing Methods 0.000 claims abstract description 12
- 239000002676 xenobiotic agent Substances 0.000 claims abstract description 7
- 239000006096 absorbing agent Substances 0.000 claims abstract description 6
- 239000004599 antimicrobial Substances 0.000 claims abstract description 6
- 239000003443 antiviral agent Substances 0.000 claims abstract description 6
- 239000000758 substrate Substances 0.000 claims description 57
- 239000000463 material Substances 0.000 claims description 51
- 239000002105 nanoparticle Substances 0.000 claims description 46
- 239000003086 colorant Substances 0.000 claims description 45
- 239000000126 substance Substances 0.000 claims description 39
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 230000036541 health Effects 0.000 claims description 21
- 230000008859 change Effects 0.000 claims description 18
- 239000004098 Tetracycline Substances 0.000 claims description 15
- 229960002180 tetracycline Drugs 0.000 claims description 15
- 229930101283 tetracycline Natural products 0.000 claims description 15
- 235000019364 tetracycline Nutrition 0.000 claims description 15
- 150000003522 tetracyclines Chemical class 0.000 claims description 15
- 230000007613 environmental effect Effects 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 12
- 239000011162 core material Substances 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 229920000742 Cotton Polymers 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 10
- 238000012377 drug delivery Methods 0.000 claims description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 10
- DYRDKSSFIWVSNM-UHFFFAOYSA-N acetoacetanilide Chemical compound CC(=O)CC(=O)NC1=CC=CC=C1 DYRDKSSFIWVSNM-UHFFFAOYSA-N 0.000 claims description 9
- 150000004056 anthraquinones Chemical class 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 210000000416 exudates and transudate Anatomy 0.000 claims description 8
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical group C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims description 7
- HLVXFWDLRHCZEI-UHFFFAOYSA-N chromotropic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(O)=CC(S(O)(=O)=O)=CC2=C1 HLVXFWDLRHCZEI-UHFFFAOYSA-N 0.000 claims description 7
- 150000002791 naphthoquinones Chemical class 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- 229930192627 Naphthoquinone Natural products 0.000 claims description 6
- 239000002417 nutraceutical Substances 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 6
- 229960001860 salicylate Drugs 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 5
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- 229960000890 hydrocortisone Drugs 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- PZTQVMXMKVTIRC-UHFFFAOYSA-L chembl2028348 Chemical compound [Ca+2].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 PZTQVMXMKVTIRC-UHFFFAOYSA-L 0.000 claims description 3
- 239000013538 functional additive Substances 0.000 claims description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 2
- 229920003043 Cellulose fiber Polymers 0.000 claims description 2
- 239000002800 charge carrier Substances 0.000 claims description 2
- 238000003851 corona treatment Methods 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 238000007641 inkjet printing Methods 0.000 claims description 2
- 239000004745 nonwoven fabric Substances 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000002759 woven fabric Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 230000002034 xenobiotic effect Effects 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000983 mordant dye Substances 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 1
- 239000008204 material by function Substances 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 235000012730 carminic acid Nutrition 0.000 description 40
- 239000004106 carminic acid Substances 0.000 description 40
- DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 description 40
- 229940114118 carminic acid Drugs 0.000 description 40
- -1 polypropylene Polymers 0.000 description 25
- 239000000725 suspension Substances 0.000 description 21
- 239000000976 ink Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000004743 Polypropylene Substances 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 11
- 239000004744 fabric Substances 0.000 description 10
- 229920001155 polypropylene Polymers 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000008177 pharmaceutical agent Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- WSALIDVQXCHFEG-UHFFFAOYSA-L disodium;4,8-diamino-1,5-dihydroxy-9,10-dioxoanthracene-2,6-disulfonate Chemical compound [Na+].[Na+].O=C1C2=C(N)C=C(S([O-])(=O)=O)C(O)=C2C(=O)C2=C1C(O)=C(S([O-])(=O)=O)C=C2N WSALIDVQXCHFEG-UHFFFAOYSA-L 0.000 description 7
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- LIKZXCROQGHXTI-UHFFFAOYSA-M acid blue 25 Chemical compound [Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC1=CC=CC=C1 LIKZXCROQGHXTI-UHFFFAOYSA-M 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- NECRQCBKTGZNMH-UHFFFAOYSA-N 3,5-dimethylhex-1-yn-3-ol Chemical compound CC(C)CC(C)(O)C#C NECRQCBKTGZNMH-UHFFFAOYSA-N 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000007797 corrosion Effects 0.000 description 4
- 238000005260 corrosion Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000004753 textile Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000003139 biocide Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical group C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000000987 azo dye Substances 0.000 description 2
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 2
- 229940015301 baicalein Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- FPVGTPBMTFTMRT-UHFFFAOYSA-L disodium;2-amino-5-[(4-sulfonatophenyl)diazenyl]benzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-UHFFFAOYSA-L 0.000 description 2
- YSVBPNGJESBVRM-UHFFFAOYSA-L disodium;4-[(1-oxido-4-sulfonaphthalen-2-yl)diazenyl]naphthalene-1-sulfonate Chemical compound [Na+].[Na+].C1=CC=C2C(N=NC3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)O)=CC=C(S([O-])(=O)=O)C2=C1 YSVBPNGJESBVRM-UHFFFAOYSA-L 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 235000019233 fast yellow AB Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 238000000733 zeta-potential measurement Methods 0.000 description 2
- WLEKZZMZTPAGDD-ZSESPEEFSA-N (2s,3s,4s,5r,6s)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid;hydrate Chemical compound O.O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 WLEKZZMZTPAGDD-ZSESPEEFSA-N 0.000 description 1
- TWJSDJTWVVOXRT-UHFFFAOYSA-N 1-ethyl-5-oxopyrrolidine-3-carboxamide Chemical compound CCN1CC(C(N)=O)CC1=O TWJSDJTWVVOXRT-UHFFFAOYSA-N 0.000 description 1
- LHENQXAPVKABON-UHFFFAOYSA-N 1-methoxypropan-1-ol Chemical compound CCC(O)OC LHENQXAPVKABON-UHFFFAOYSA-N 0.000 description 1
- JMEVHYCNAPFOAB-UHFFFAOYSA-L 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [O-]c1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=[NH+]c2ccc(cc2C1=O)S([O-])(=O)=O JMEVHYCNAPFOAB-UHFFFAOYSA-L 0.000 description 1
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical group C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- QUIGZRGHRCBCRU-UHFFFAOYSA-N 4,5-dihydroxy-3-[(4-sulfophenyl)diazenyl]naphthalene-2,7-disulfonic acid Chemical compound OC1=C2C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=C1N=NC1=CC=C(S(O)(=O)=O)C=C1 QUIGZRGHRCBCRU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- NBBMVUMNUONMLW-UHFFFAOYSA-N Albofungin Natural products COC1CCC(O)C2=C1Oc3c4OCOC5Cc6cc7C=C(C)N(N)C(=O)c7c(O)c6c(cc3C2=O)c45 NBBMVUMNUONMLW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- GXEAXHYQKZAJGB-UHFFFAOYSA-L acid red 29 Chemical compound [Na+].[Na+].OC1=C2C(O)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 GXEAXHYQKZAJGB-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- LYKFTVCDYGGLGW-BFHYXJOUSA-N albofungin Chemical compound C1=C(C)N(N)C(=O)C(C(O)=C23)=C1C=C3C[C@@H](OCOC1=C3C4=O)C1=C2C(O)=C3OC1=C4[C@@H](O)CC[C@H]1OC LYKFTVCDYGGLGW-BFHYXJOUSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000006149 azo coupling reaction Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019846 buffering salt Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- LNXMADNIUWFTPP-UHFFFAOYSA-L chembl2028186 Chemical compound [Na+].[Na+].OC1=CC=C(Cl)C=C1N=NC1=C(O)C2=C(O)C=C(S([O-])(=O)=O)C=C2C=C1S([O-])(=O)=O LNXMADNIUWFTPP-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- NHFDKKSSQWCEES-UHFFFAOYSA-N dihydrogen phosphate;tris(2-hydroxyethyl)azanium Chemical compound OP(O)(O)=O.OCCN(CCO)CCO NHFDKKSSQWCEES-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000434 metal complex dye Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 238000001485 positron annihilation lifetime spectroscopy Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- ORIHZIZPTZTNCU-YVMONPNESA-N salicylaldoxime Chemical compound O\N=C/C1=CC=CC=C1O ORIHZIZPTZTNCU-YVMONPNESA-N 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/31—Artificial sweetening agents containing amino acids, nucleotides, peptides or derivatives
- A23L27/32—Artificial sweetening agents containing amino acids, nucleotides, peptides or derivatives containing dipeptides or derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/06—Aluminium compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
- A23L27/77—Use of inorganic solid carriers, e.g. silica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- a delivery system generally refers to a system that aids or otherwise facilitates the delivery of a functional material to a desired location.
- the functional material can be any material that acts upon a substrate or otherwise provides a benefit once delivered to the desired location.
- Examples of functional materials that may benefit from the use of a delivery system include pharmaceuticals that are intended to be ingested, topically applied, or subcutaneously injected into a patient, fragrances, vitamins and nutrients, and various other and numerous additives.
- the functional material can be a dye that is intended to be printed or otherwise applied to a substrate.
- various delivery systems for dyes have been proposed that are intended to facilitate application of the dye to a substrate, such as a textile material.
- the delivery systems are intended to affix the dye to a substrate, prevent the dye from fading when exposed to sunlight, to prevent the dye from degrading when exposed to the environment, to facilitate application of the dye to the substrate, or, for example, to render the dye more stable.
- dyes a need also exists in the art for a delivery system for a dye that is capable of affixing the dye to negatively charged surfaces.
- a need also exists in the art for a delivery system for such materials that is capable of affixing the pharmaceutical or other health -related compounds to the delivery system.
- a need also exists for a delivery system that will readily and /or selectively release such pharmaceutical materials upon the occurrence of a selected event or trigger.
- a need also exists for a method for selectively triggering the release of a pharmaceutical material or other health- related compound where and when it is needed.
- the present invention is generally directed to a delivery system for various functional materials.
- the functional materials can be, for instance, colorants, UV absorbers, pharmaceuticals, odor control agents, fragrances, anti-microbial agents, anti-viral agents, antibiotics, xenobiotics, nutriceutical agents (nutritional materials), and the like.
- the functional materials are adsorbed onto a particle.
- the functional materials are absorbed onto silica particles or alumina that is contained in/on a particle.
- the resulting particle can then be used as is or can be combined with a vehicle, such as a liquid vehicle, to deliver the functional material to a desired location.
- the resulting particle, or particle containing vehicle can be incorporated into a drug delivery device, such as a bandage or tampon.
- the particles of the present invention can be incorporated into a liquid vehicle and applied to a substrate using any conventional printing means.
- the functional material is a health related compound such as a pharmaceutical or nutritional compound
- the particles can likewise be incorporated into a vehicle and applied to a substrate such as a bandage or drug delivery device which can be placed immediately adjacent, in contact with or within a patient's body.
- the term "patient's body” shall mean a human or animal body.
- the functional material can be delivered to a selected location on or within a patient's body.
- such particles could be taken by a patient internally where appropriate to deliver the functional material to a desired location.
- the functional material may be triggerably released from a particle at a selected location or time, following occurrence of a triggering event, such as exposure to a chemical, body exudates or moisture or environmental stimuli, such as a change in pH.
- the present invention is directed to a particle containing alumina. At least a portion of the alumina contained within the particle is present on a surface of the particle. A functional compound is bonded to the alumina on the surface of the particle. The functional compound prior to bonding with the alumina contains a moiety comprising one or more of:
- R and R' comprise independently hydrogen, an alkyl group, or an aryl group.
- the above moieties can be present as is on a functional compound.
- each of the above moieties can include further R groups attached to the carbon chain shown above.
- any such R group can appear in association with the above moieties as long as the R group does not interfere with the bonding of the moiety to an alumina.
- the above moieties have been found to form a bond with alumina in constructing the compositions of the present invention.
- the functional compound in some embodiments, can bond with alumina without significantly changing the positive charge character of alumina. For example, under certain conditions, alumina may have a positive surface charge. It has been discovered that even after the functional material is bonded to the alumina, the resulting structure still maintains a positive charge.
- positively charged particles are formed. Due to their positive charge, the particles may be securely affixed to the surface of a substrate that carries with it a negative charge through coulombic attraction.
- novel recording mediums, inks, and nanoparticles containing a colorant compound may be formed.
- such recording mediums when applied to substrates, exhibit improved water and detergent resistance.
- the delivery system of the present invention can improve the durability performance of the recording mediums especially to substrates having a negative charge.
- a recording medium such as an ink-jet ink
- a recording medium can be produced according to the present invention that is substantive to substrates containing synthetic polymeric fibers, such as polypropylene fibers, polyethylene fibers, polyester fibers, and the like.
- the functional agent such as the pharmaceutical may be selectively released from the carrier particle (such as an alumina, silica, or alumina coated silica particle) so as to release the pharmaceutical at a targeted/desirable body location, or at a desirable moment.
- the carrier particle such as an alumina, silica, or alumina coated silica particle
- such selective release can be accomplished by exposure of the particle to a change in environmental condition, such as a pH change.
- a pH change such selective release may be accomplished by exposure to an alkaline environment.
- such selective release my be accomplished by exposure to an acidic environment.
- such selective release may be the result of exposure of the carrier particle to particular chemical stimuli.
- a method for applying a health related compound utilizes a health-related compound coated particle, and selectively releasing the compound upon exposure of the particle to either a change in environmental condition, or upon exposure to a chemical stimuli.
- the functional compounds can in one embodiment, be selectively released in either a basic or acidic environmental condition.
- the functional compounds can be released in the basic/alkaline environment of a vagina experiencing a yeast infection.
- the functional compounds can be released in the basic environment of the small intestine so as to treat an infection, after passing through the acidic environment of the stomach.
- a functional compound may be released as a result of environmental stimuli as an alert or in conjunction with the completion of the delivery of a pharmaceutical material so as to provide and indication of such delivery or the success of such treatment.
- such indicator may be released as a result of appearance of moisture or body fluids.
- Such indicator or signal may be in the form of a dye or fragrance.
- such indicator or signal may be the result of a functional material contained on a first type of particle, and such coated particle may be included with additional particles of a different variety, that contain health related compounds (pharmaceutical and/or nutritional compounds).
- the functional material may be released in response to a particular chemical stimuli, which is intentionally applied to the site of the carrier particles.
- a method of utilizing a triggerably releasable delivery system in the treatment of a patient's body includes the steps of providing at least one type of particle selected from alumina particles, alumina covered particles, and silica particles; adsorbing at least one health related functional compound to the surface of the particle or particles to form at least a partially coated particle or particles; exposing the at least partially coated particle or particles to a patient's body such as by ingestion, injection, transdermal transfer or transmucosal transfer; and exposing the particle or particles to an environmental or chemical condition whereby the health related compound is released from the surface of the particle to the patient's body (which could be either an animal or human body).
- such health related compound is released from particles contained on a drug delivery device, but because of charge attraction (as previously described) the particles themselves remain affixed to the drug delivery device.
- a triggerable delivery system includes a particle selected from silica, alumina or alumina coated particles; and a health-related compound adsorbed to the surface of the particle, the health-related compound capable of being released from the particle upon either exposure to a change in pH, moisture, chemical stimuli, or body exudates.
- the triggerable delivery system includes a particle containing alumina, at least a portion of the alumina being present on a surface of the particle; and a health related compound adsorbed to the alumina surface of the particle, the health related compound, prior to being adsorbed with the alumina on the surface of the particle containing a moiety including at least one of
- R and R' comprise independently hydrogen, an alkyl group, or an aryl group.
- a drug delivery device such as a topical bandage or a tampon, includes a triggerable delivery system.
- the triggerable delivery system includes a particle; and a health-related compound adsorbed to the surface of the particle, with the health-related compound capable of being released from the particle upon either exposure to a change in pH, moisture, chemical stimuli, or body exudates.
- the present invention is directed to a delivery system for functional compounds.
- Functional compounds can be any suitable substance that can provide a benefit to a location once delivered.
- the delivery system is generally directed to the construction of a particle.
- a particle may be either silica or desirably containing alumina.
- the alumina contained within the particle provides a bonding site on the surface of the particle for a functional compound.
- the functional compound becomes adsorbed onto the surface of the alumina (or silica, if it is an entirely silica particle).
- the resulting particle can then be used to deliver the functional compound to a particular location.
- the particles can be used as is, for instance, or can be combined with a ( lid vehicle which may facilitate delivery of the particles depending upon the particular application.
- the particles or liquid vehicles containing the particles may further be placed within a drug delivery device such as a tampon, bandage or other transdermal delivery device.
- a functional equivalent to one of the above moieties refers to functional materials that include similar reactive groups as shown above, but which are not positioned on a molecule as exactly shown above and yet will still bond with alumina in a similar manner. Referring to the moieties shown above, moiety (1 ) may be considered a carboxy-hydroxy moiety. Moiety (2) may be considered a hyrdoxy-hydroxy moiety, while moiety (3) may be considered a carboxy-carboxy moiety. Moieties (4) and
- the amine groups can be primary amines, secondary amines, or tertiary amines.
- Moieties (6) and (7) may be considered hydroxyl carbonyl moieties.
- Moiety (8) may be considered a carboxy amine. Moieties such as (8) may be found in amino acids.
- Moiety (9) may be considered a hydroxy imine.
- any suitable functional compound containing one of the above moieties or a functional equivalent thereof may be used in accordance with the present invention. Further, it should be understood that various additional R groups may be included with the above moieties as long as the R groups do not interfere with the bond that is formed with alumina.
- the present inventors have discovered that the above moieties may form a relatively strong bond to at least an alumina surface.
- the functional compounds may be bonded to the alumina surface in order to change the properties of the resulting particle or to perform a particular function.
- the above moieties form a bidentate ligand bonding system with alumina surfaces.
- alumina forms a covalent bond and a coordinate bond with the above moieties.
- a surface reaction occurs causing the functional compound to remain on the surface of the particle and form a coating thereon.
- the functional material can cover the entire resulting particle or can be located at particular locations on the particle.
- the particles of the present invention can contain more than one functional compound, or alternatively, numerous different particles can contain/include different functional compounds.
- zeta potential is used herein to mean without limitation a potential gradient that arises across an interface. This term especially refers to the potential gradient that arises across the interface between the Stern layer in contact with the particle of the present invention and the diffuse layer surrounding the particle. Zeta potential measurements can be taken using, for instance, a Zumblels instrument which are available from the Brookhaven Instrument Corporation of Holtsville, New York.
- zeta potential measurements can be conducted by adding one to three drops of a sample into a cuvet containing 1 mM KCI solution, using the instrument's default functions preset for aqueous solutions.
- the resulting molecule continues to maintain a relatively strong positive charge.
- particles made according to the present invention can have a zeta potential of greater than 20 mV, particularly greater than 30 mV, and, in some embodiments, greater than 40 mV. By remaining positively charged, the particles are well suited for being affixed to substrates that carry a negative surface charge through coulombic attraction.
- the bond of the particle in some applications can be relatively permanent and substantive. Consequently, the delivery system of the present invention can be used to affix functional compounds to various substrates without the use of chemical binders or other attachment structures.
- the functional compound/agent may be selectively released from the particle.
- the carrier particle delivery system
- the carrier particle can include along its surface a pharmaceutical functional compound, and yet the particle may still retain sufficient positive charge, to allow it to be attached to a negatively charged bandage or other topically contacting substrate layer. Then upon the occurrence of a specific chemical or environmental stimuli, the functional material contained on the particle can be selectively released to the body of a patient, but the carrier particles will remain affixed to the bandage or other charged surface.
- alumina or silica particles may be used, depending upon the functional compound and the trigger for releasing it.
- Silica particles are available under the designation SNOWTEX-C through from Nissan Chemical America (Houston , TX).
- Various different particles and compositions that contain Alumina can be used in the present invention.
- the functional material is combined with an alumina sol.
- Many different types of alumina sols are commercially available with varying particle size.
- alumina sols can be prepared that carry a relatively strong positive surface charge or zeta potential.
- the particle that is reacted with the functional compound contains primarily and in some embodiments exclusively alumina.
- alumina particle materials include Aluminasol- 100, and Aluminasol-200, available from Nissan Chemical America (Houston , TX).
- the alumina particle reacted with the functional compound can contain various other ingredients.
- the particle can contain any material that does not adversely interfere with ability of the functional material to bond to alumina.
- at least a portion of the alumina contained by the particle should be present on the surface of the particle so that the alumina is available for adsorbing the functional compound.
- the particle can contain a core material coated with alumina.
- the alumina can form a continuous coating over the particle or a discontinuous coating.
- the core material can be, for instance, an inorganic oxide, such as silica.
- sols can be used that contain silica nanoparticles that have an alumina surface coating. Such sols are currently commercially available, for instance, from Nissan Chemical America of Houston, Texas.
- the silica is coated with alumina to provide stability to the sols over certain pH ranges.
- alumina coated silica sols may have greater stability in some applications of the present invention in comparison to alumina sols.
- a specific example of alumina particle materials with silica cores include Snowtex-AK, available from Nissan Chemical America, ( Houston, TX) and Ludox CI from Grace Davison, Columbia, MD.
- any suitable functional compound containing one of the above moieties, a tautomer thereof, or a functional equivalent thereof may be used in accordance with the present invention.
- functional compounds include health related compounds such as pharmaceuticals, and xenobiotics. Xenobiotics is a general term used to describe any chemical interacting with an organism that does not occur in the normal metabolic pathways of that organism.
- Other functional compounds can include UV absorbers, odor control agents, fragrances, therapeutic agents, nutriceutical agents, anti-viral agents, antimicrobial agents, signal agents and the like.
- a therapeutic agent that may be used in the present invention is hydrocortisone.
- nutriceutical agents include ascorbic acid and aspartame.
- the functional compound may be tetracycline, which is a known antibacterial agent.
- the functional compound can be a colorant, such as dye. Particular examples of dyes that may be used in accordance with the present invention are discussed in greater detail below.
- the particle structure can be incorporated into liquid vehicles, can be formed into capsules, can be combined with gels, pastes, other solid materials, and the like.
- the particles can also be incorporated into drug delivery devices such as bandages and tampons.
- the particles formed according to the present invention and the functional compound can be present in various forms, shapes, and sizes depending upon the desired result.
- the particles can be of any shape, for example, a sphere, a crystal, a rod, a disk, a tube, or a string of particles.
- the size of the particle can also vary dramatically.
- the particles can have an average dimension of less than about 1 mm, particularly less than about 500 microns, and more particularly less than about 100 microns.
- the particles can have an average diameter of less than about 1 ,000 nm, and particularly less than about 500 nm.
- the average dimension of a particle refers to the average length, width, height, or diameter of a particle.
- the particles of the present invention include a surface layer that contains one or more functional compounds.
- the coating on the particle can be continuous or discontinuous.
- the particle itself is believed to be amorphous.
- the present invention is directed to a delivery system for dyes.
- the use of alumina as described above provides various advantages and benefits when attempting to apply a dye to a substrate.
- the alumina delivery system can provide a means to make permanent prints onto substrates having negatively charged surfaces, such as substrates containing thermoplastic polymers as well as natural fibers. The ink becomes affixed to the substrate at relatively low cost and low complexity without the use of chemical binders and without the use of a pre-treatment or post-treatment process on the substrate.
- the resulting particle has a positive charge.
- the particle can be affixed to negatively charged surfaces through coulombic attraction.
- the dye may exhibit permanent properties such as wash fastness by being resilient to water and detergents. For example, generally wash fastness can be obtained if the charge difference between the substrate and the particle is greater than about 42 mV.
- any dye containing a carbonyl-hydroxy moiety, a hydroxy- hydroxy moiety, a carbonyl-carbonyl moiety, a vinylalagous amide moiety, a tautomer thereof, or a functional equivalent thereof as described above, or any of the other moieties may be used in the process of the present invention.
- Various examples of dyes that may be adsorbed onto alumina are as follows. It should be understood, however, that the below list is not exhaustive and is not intended as limiting the invention.
- Numbers indicate the substitution positions of the anthraquinone structure.
- This table indicates dye substituents that occur at positions 1 , 4, 5, or 8 on the anthraquinone structure. In other words, this table shows the presence of groups that form alumina bonding moieties 1 through 5.
- Dyes based upon Chromotropic acid 8 are also substantive to alumina. Azo dyes are formed when chromotropic acid is reacted with a diazonium salt. Azo coupling occurs at positions 2 and / or 7.
- Dyes containing acetoacetanilide moieties 9 also contain the correct geometry to bond to alumina. Azo dyes couple to acetoacetanilide beta to the two carboxyl groups. An example is CI Acid Yellow 99, 10. Acetoacetanilide will adsorb onto
- Naphthoquinone (11) type Structures are also useful for forming complexes with the surface of alumina: o OH
- CI Natural Black 1 is another example of a dye that contains quinoid groups and is substantive to alumina.
- Aluminum Dyes Dyes Known to be Useful for Staining Anodized Aluminum.
- CI Mordant Red 7 Eriochrome Red B
- the geometry of the five membered pyrazolone ring oxygen atom brings it into the correct position with the beta-naphthol group for complexation with alumina.
- the following structure can be considered a functional equivalent to a carbonyl-hydroxy moiety.
- the structure also contains an iminalogous amide moiety, which is functionally equivalent to a vinalogous amide.
- Certain anionic dyes may be precipitated using certain metal ions to form insoluble colored compounds know as Lake Pigments.
- Erythrosine Tetraiodofluorescein
- the salt is known as CI Pigment Red 172.
- CI Pigment Blue 36 is the aluminum lake of indigo disulfonate (FD+C Blue 1 ):
- additives that assist in the dyeing process or that stabilize the dye may also be bonded to the alumina if the additive contains a moiety as described above.
- functional additives include charge carriers, thermal oxidation stabilizers, crosslinking agents, plasticizers, a charge control additive, a flow control additive, a filler, a surfactant, a chelating agent, a colorant stabilizer, or a combination thereof.
- Various methods can be utilized to construct dye particles in accordance with the present invention that contain a dye adsorbed onto alumina. For instance, in some applications, the alumina and the dye containing a reactive moiety can be combined and reacted in an aqueous solution.
- the dye may be difficult to dissolve in water.
- the dye can first be dissolved in a minimum quantity of a solvent.
- the solvent can be, for instance, acetone, ethanol or a similar liquid that is miscible with water.
- a surfactant can be added in an amount greater than about 0% to about 50% by weight of dye solids added. In general, the amount of surfactant added to the solvent should be minimized.
- the dissolved dye solution can then be added to a dilute aqueous suspension that contains particles comprising alumina.
- aqueous suspension is slightly heated.
- the dye disperses by precipitation throughout the mixture and slowly dissolves into the water. Once dissolved into the water, the dye can be adsorbed by the alumina contained in/on the particles. Once the dye is adsorbed onto the alumina, the resulting particles can be used to formulate a suitable colorant composition for use in various processes, such as in a suitable printing process.
- the colorant composition may comprise an aqueous or non-aqueous medium, although an aqueous medium is useful for applications which employ liquid printing mediums.
- the colorant compositions of the present invention contain particles, as well as, desirable colorant stabilizers and additives.
- the colorant composition may contain the above-described particles in combination with any of the following additives: a second colorant; a colorant stabilizer, such as a porphine; a molecular includant; a pre-polymer; and any additional components as described above.
- the present invention encompasses recording mediums such as ink jet inks comprising the nanoparticles disclosed herein.
- Inks used in ink jet printers are described in U.S. Patent No. 5,681 ,380, assigned to Kimberly-Clark Worldwide, Inc., which is incorporated herein by reference in its entirety.
- Ink jet inks will usually contain water as the principal solvent, preferably deionized water in a range of between about 20 to about 95 percent by weight, various co-solvents in an amount of between about 0.5 and about 20 percent by weight, and the particles of the present invention.
- co-solvents may also be included in the ink formulation.
- co-solvents include a lactam such as N-methyl pyrrolidone.
- other examples of optional co-solvents include N-methylacetamide, N-methylmorpholine- N-oxide, N,N-dimethylacetamide, N-methyl formamide, propyleneglycol- monomethylether, tetramethylene sulfone, and tripropyleneglycolmonomethylether.
- Still other solvents which may be used include propylene glycol and triethanolamine (TEA).
- TAA triethanolamine
- an acetamide-based cosolvent is also included in the formulation it is typically present at about 5 percent by weight, within a range of between about 1.0-12 percent by weight.
- one or more humectants in an amount between about 0.5 and
- Additional humectants for optional use in the formulation include, but are not limited to, ethylene glycol, diethylene glycol, glycerine, and polyethylene glycol 200, 400, and 600, propane 1 ,3 diol, other glycols, a propyleneglycolmonomethyl ether, such as Dowanol PM (Gallade Chemical Inc., Santa Ana, CA), polyhydric alcohols, or combinations thereof.
- additives may also be included to improve ink performance, such as a chelating agent to sequester metal ions that could become involved in chemical reactions that could spoil the ink over time, for example for use with metal complex dyes, a corrosion inhibitor to help protect metal components of the printer or ink delivery system, a biocide or biostat to control unwanted bacterial, fungal, or yeast growth in the ink, and a surfactant to adjust the ink surface tension.
- a surfactant may be dependent on the type of printhead to be used. If a surfactant is included, it is typically present in an amount of between about 0.1 to about 1.0 percent by weight. If a corrosion inhibitor is included, it is typically present in an amount between about 0.1 and about 1.0 percent by weight.
- a biocide or biostat is included, it is typically present in an amount between about 0.1 and about 0.5 percent by weight. If a biocide or biostat is added to the ink formulation, it may be exemplified by Proxel GXL (Zeneca Corporation, Wilmington, Delaware). Other examples include Bioban DXN (Angus Chemical Company, Buffalo Grove, Illinois). If a corrosion inhibitor is added to the formulation, it may be exemplified by Cobratec (PMC Specialty Group Distributing of Cincinnati, Ohio). Alternate corrosion inhibitors include sodium nitrite, triethanolamine phosphate, and n-acyl sarcosine. Still other examples include benzotriazole (Aldrich Chemical Company, Milwaukee, Wisconsin).
- a surfactant is included in the formulation, it is typically a nonionic surfactant exemplified by Surfynol 504 (Air Products and Chemicals, Inc., Allentown, Pennsylvania). Still other examples include Surfynol 465, and Dynol 604 also available from Air Products.
- a chelating agent is included in the formulation it may be exemplified by an ethylene diaminetetraacetic acid (EDTA).
- EDTA ethylene diaminetetraacetic acid
- Other additives such as pH stabilizers/buffers, (such as citric acid and acetic acid as well as alkali metal salts derived therefrom), viscosity modifiers, and defoaming agents such as Surfynol DF-65, may also be included in the formulation, depending on the product application.
- the composition can be used in various printing processes.
- the colorant composition can be used in screen printing processes, offset lithographic processes, flexographic printing processes, rotogravure printing processes, and the like.
- a thickener may need to be added to the colorant composition.
- the thickener can be, for instance, an alginate.
- the recording medium or colorant composition of the present invention may be applied to any substrate to impart a color to the substrate.
- the substrate to which the composition is applied may include, but is not limited to, paper, wood, a wood product or composite, woven fabrics, non-woven fabrics, textiles, films, plastics, glass, metal, human skin, animal skin, leather and the like.
- the colorant composition or recording medium may be applied to textile articles such as clothing.
- a colorant composition containing particles of the present invention may be applied to a substrate having a negative surface charge.
- the alumina contained in the particles of the present invention retain a positive charge even after adsorption of a dye. Consequently, the particles remain affixed to negatively charged surfaces.
- wash durability of the colorant composition may occur if there is a substantial amount of charge difference between the substrate and the particles of the present invention.
- colorant compositions made according to the present invention are particularly well suited to being applied to natural and synthetic substrates that have a negative surface charge.
- naturally occurring materials that generally contain a negative surface charge include cotton fibers, cellulose fibers, and substrates made therefrom.
- Such substrates include all types of fabrics, garments and apparel, paper products, and the like.
- colorant compositions made according to the present invention have been found to be well suited to being applied to substrates made from synthetic polymers, such as thermoplastic polymers.
- substrates can include, for instance, woven and non-woven materials made from a polyolefin polymer such as polypropylene or polyethylene, polyester, and the like.
- polyolefin polymer such as polypropylene or polyethylene, polyester, and the like.
- various problems have been experienced in trying to affix dyes to these types of materials. Consequently, either complicated dye structures have been used or dyes and or pigments have been applied in conjunction with chemical binders.
- the particles of the present invention can permanently affix to these materials without the use of chemical binders or complex chemical constructions.
- substrates made from synthetic polymers can undergo a pretreatment process for increasing the negative surface charge.
- pretreatment processes include subjecting the substrate to a corona treatment or to an electret treatment.
- An electret treatment for instance, is disclosed in U.S. Patent No. 5,964,926 to Cohen, which is incorporated herein by reference in its entirety.
- Such pretreatments have been found not only to increase the negative surface charge of polymeric materials, but also assist in wetting out the polymer and enhancing surface adhesion between the polymer and the particles of the present invention.
- substrates contacted with the particles of the present invention can also undergo various post treatment processes which further serve to affix the particles to the substrate.
- the treated substrate can be subjected to radio frequency radiation or to microwave radiation.
- Alumina is known to adsorb radio frequency radiation and microwave radiation causing the particles to heat. Once heated, it is believed that the particles become further embedded into the polymeric substrate. Further, the particles can be heated without also heating the substrate to higher than desired temperatures.
- functional compounds health- related compounds
- coated particles can be applied topically to a patient's body either directly, or with the assistance of a drug delivery device, such as a modified bandage, tampon, or other known transdermal delivery apparatus. Alternatively, such coated particles may be taken internally through various mechanisms.
- Aluminasol 200 (Nissan Chemical America) was diluted with Dl water to give a 2% Aluminasol 200 suspension. Meanwhile, carminic acid (0.02g) was suspended in Dl water (1g). Carminic acid includes hydroxy-carbonyl moieties and can be represented as follows:
- the positively charged alumina was capable of adsorbing carminic acid without going through a charge reversal step.
- Aluminasol 200 (Nissan Chemical America, 2 g) was diluted with Dl water (98g) with good stirring.
- Carminic acid (Aldrich, #22,925-3) (0.5011g) was suspended in Dl water (23.7135 g) with good stirring. The carminic acid did not dissolve completely at this concentration, and so whenever portions were taken, they were taken while stirring vigorously so that suspended solids were also withdrawn.
- a hypodermic syringe was used to withdraw 1 ml of carminic acid suspension. This was added to the diluted Aluminasol 200 with good stirring. The suspension changed from a white to a bluish red.
- the Zeta potential was monitored after addition to check for changes as follows:
- CI Acid Blue 25 and CI Acid Blue 45 were bonded to alumina in accordance with the present invention.
- CI Acid Blue 25 and CI Acid Blue 45 have the following structures:
- CI Acid Blue 25 0.2008 g CI Acid Blue 25 (Aldrich) was added to 19.7735 g Dl water and stirred to give a suspension, which was stirred for 30 minutes. 1 ml of this was added to a mixture containing 2g Aluminasol and 98g Dl water. Mixture stirred overnight to ensure that all dye had dissolved.
- CI Acid Blue 45 (Aldrich) was suspended in 20.1751 g Dl water with stirring for 30 minutes. 1 ml (syringe) was added to a mixture of 2g Aluminasol and 98g of Dl water to give a blue complex. Mixture stirred overnight to ensure that all dye dissolved.
- Aluminasol 200 a high concentration of Aluminasol 200 was combined with carminic acid. Specifically, 0.111g glacial acetic acid (Fischer, ACS plus reagent grade) was diluted with 29.795g Dl water. This was added to 49.941g of Aluminasol 200, slowly with good stirring. This mixture was stirred for 20 mins, at which point, 4ml (measured using a syringe) of a suspension of carminic acid in Dl water (0.5011g carminic acid in 23.7135g water) was added at once, with good stirring. Mixture stirred overnight. A fourth sample was then constructed containing the same ingredients (carminic acid) in the same amounts as listed in Example 2 above.
- the above three solutions were then subjected to a dialysis test to demonstrate that the dye was adsorbed onto the alumina surfaces.
- the three solutions were dialyzed against 3% glacial acetic acid using Sigma Dialysis Tubing (Cellulose, 12,000mw cut off, Sigma D-0655. Tubing was soaked in Dl water for two hours prior to use to remove glycerine, and to make the tubing flexible.)
- Sigma Dialysis Tubing Cellulose, 12,000mw cut off, Sigma D-0655. Tubing was soaked in Dl water for two hours prior to use to remove glycerine, and to make the tubing flexible.
- a small amount of carminic acid was added to a dialysis tubing and placed in a bath containing 3% acetic acid. Within 2 hours, carminic acid had traversed the cellulose membrane and had colored the 3% acetic acid solution.
- a control sample was also prepared.
- a carminic acid solution was first formulated containing 0.5011 grams of carminic acid in 23.7135 grams of Dl water.
- the carminic acid solution was dropped onto cotton poplin fabric using a pipette and allowed to dry overnight at 60°C.
- Samples were washed by i) rinsing under a hot running tap, and then by stirring for 2 hours in 2 liters of water containing 1 g / liter Aerosol OT (dioctyl sodium sulfosuccinate surfactant obtained from Cytec Industries of West Patterson, New Jersey) and 1 g / liter of sodium bicarbonate, with stirring (mechanical paddle stirrer). Samples were entered into the washing bath at 60°C, and the bath cooled over two hours to 30°C. The fabric was rinsed in cold water, then dried in the air at ambient.
- Aerosol OT dioctyl sodium sulfosuccinate surfactant obtained from Cytec Industries of West Patterson, New Jersey
- the following tests were conducted to demonstrate the washfastness of particles made according to the present invention on a polypropylene non-woven spunbond fabric.
- the spunbond fabric tested had a basis weight of 2 osy.
- Polypropylene spunbond was smeared with i) carminic acid, ii) the concentrated 50% Aluminasol / carminic acid complex suspension prepared in Example 3 and iii) the 2% Aluminasol / carminic acid complex suspension prepared in Example 3.
- the polypropylene was difficult to wet out with these materials, and so smearing was required using a rubber-gloved finger and the teat pipette used to apply the liquids. Once the material had been smeared on forcibly, the material showed little retraction. The samples were allowed to dry overnight at 60°C. More polypropylene was smeared with the 50% Aluminasol / carminic acid complex.
- a sol containing silica particles that had an alumina surface coating were used instead of using an alumina sol.
- the surface coated silica suspension was obtained from Nissan Chemical America of Houston, Texas. The suspension is sold under the trade name SNOWTEX-AK.
- the physical parameters of the nanoparticles are:
- Tetracycline is an antibacterial agent that contains a carbonyl-hydroxy function capable of bonding with alumina in accordance with the present invention. Tetracycline is a series of isomers of cyclomycin. Tetracycline contains as a principle component the following:
- the UV-visible absorbance spectrum of Tetracycline was measured using a UV-visible spectrophotometer (Perkin-Elmer UV-Visible spectrophotometer.) Tetracycline was found to absorb at 357nm in water. When SNOWTEX AK suspension (as described in Example 6) was added to the tetracycline solution, a bathochromic shift occurred to give an absorbance of 365 nm, suggesting that the tetracycline had adsorbed onto the alumina surface of SNOWTEX AK particles.
- agents were evaluated for their propensity to bind strongly to alumina particles. They included the agents described in the following table, and which demonstrated the noted shift. These agents are considered antineoplastic for use as drugs that kill or stop the spread of cancer cells. Baicalein has been studied for its antiproliferation effect of human T- lymphoid leukemia cells.
- Still additional pharmaceutical agents which may be used in conjunction with this invention include the following materials.
- nutraceutical agents with the desired functional moieties were evaluated for their propensity to bind to alumina particles.
- examples of such compounds were ascorbic acid (Vitamin C) and phenylalanine (sweetener found in Equal®).
- the structural equations for these materials and their ability to bind to such particles was demonstrated as can be seen in the table which follows:
- compositions were adsorbed to carrier alumina particles and then selectively released from the carrier particles.
- alumina nanoparticle SNOWTEX- AK
- a bathochromic shift red shift
- UV-VIS Lambda maxima was again observed, indicating strong binding of these pharmaceutical agents to the surface of the alumina particle.
- the following Table shows the shift in the UV-VIS spectra recorded.
- the pharmaceutical agent was released as observed by a second red shift of the UV-VIS Lambda Maxima.
- the alkaline agent dilute sodium hydroxide (0.1 N)
- the tetracycline was released from the alumina surface when the suspension of modified nanoparticles was altered to pH 9/10 or greater.
- the noted shifts correspond to the absorption maximum of the free pharmaceutical agents.
- these two examples of pharmaceutical agents demonstrate the capability of selectively releasing pharmaceutical agents from the carrier particles.
- a "pH trigger” the functional compounds can be released in a controlled manner when needed.
- Chemistries that may be introduced to a delivery system include bicarbonates, carbonates and buffering salts which would result in a pH change on becoming wet with water or biological fluid.
- a signal agent such as a fragrance
- a fragrance may be adsorbed to one type of particle and an antibiotic may be adsorbed to a second type of particle.
- the particles can be delivered to an infected site simultaneously. If the infected site is alkaline, it will prompt the release of the antibiotic. Upon removal of the infection, and the return to a more normal acidic environment, the fragrance may be released, thereby providing an indication of the effective treatment of the infection.
- the signal can be used to generate an indication of a particular event, such as the release of body fluids or exudates as in a bandage or personal care product, such as a feminine care product or child care diaper product.
- a method used to prepare alumina nanoparticles having functional compounds bonded to the surface included the following steps.
- the functional compound was dissolved in water with stirring. To this stirred solution was slowly added the alumina nanoparticles and the resulting mixture stirred for about 5 to 10 minutes to allow the functional compound to bond to the surface of the nanoparticle.
- the UV-VIS spectrum of the water solution was obtained by taking an aliquot of the stirred mixture and placing it in a quartz cell. The UV-VIS spectra were obtained using a UV-VIS spectrophotometer Model UV- 1601 (Shimadzu Corporation) with water as a reference. Zeta Potential and particle size measurements were determined using a ZetaPals Instrument (Brookhaven Instrument Company, Holtsville, NY).
- a method used to release the bonded functional compound utilizing a pH trigger included the following steps.
- the alumina nanoparticle having the functional agent bonded to the surface was placed in an aqueous solution (suspension) with stirring.
- dilute sodium hydroxide (0.1 N) dropwise was slowly added to this stirred suspension.
- An aliquot of this suspension was taken and the UV-VIS spectrum measured.
- the bonded functional agent's Lambda max peak can be observed to decrease with the free functional agent's Lambda max peak observed to appear and increase.
- the delivery system would be incorporated into a tampon.
- Normal healthy vaginal fluid is acidic, typically in the 3-5 pH range. However, when infected with a yeast infection or other microbial infection, the pH changes to the basic range. This swing in pH would trigger the release of medication such as tetracycline or buffering agents to restore the healthy pH of the vaginal fluid and flora.
- a medicated tampon may include a bound antibiotic ("bound" meaning the functional compound adsorbed to the surface of nanoparticles which are themselves attached through charge attraction to a tampon substrate).
- nanoparticle delivery systems may be employed to carry the pharmaceutical agent through the stomach (having an acidic environment) and then release the agents into the small intestine (having a basic/alkaline environment).
- such nanoparticle delivery systems may be triggered upon the appearance of moisture or body exudates, or application of a pH changing chemistry. In these situations, functional materials contained on carrier nanoparticles on a bandage can be selectively released into or onto a wound site. Examples of Signal Systems Which Can be Used to Indicate the Release of Pharmacutical Agents Upon a Change in Environmental Condition:
- the following examples illustrate the use of silica nanoparticles (as opposed to alumina particles) and the bonding of signal functional agents to the surface of the particles.
- the pH triggered release for silica coated particles is activated by adding acid and lowering the pH to the environment of the silica particles . Dilute acid is used in these examples.
- a method used to prepare silica nanoparticles having functional agents bonded to the surface included the following steps. The functional agent was dissolved into water with stirring. To this stirred solution was slowly added the silica nanoparticles and the resulting mixture stirred for about 5 to10 minutes to allow the functional agent to bond to the surface of the nanoparticles.
- the UV-VIS spectrum of the water solution was obtained by taking an aliquot of the stirred mixture and placing it in a quartz cell.
- the UV-VIS spectra were obtained using the UV-VIS spectrophotometer Model UV-1601 with water as a reference.
- Zeta Potential and particle size measurements were determined using a ZetaPals Instrument (Brookhaven Instrument Company, Holtsville, NY).
- a method used to release the bonded functional agent from the silica surface using a pH trigger included the following steps.
- the silica nanoparticle having the functional agent bonded to the surface was placed in aqueous solution (suspension) with stirring.
- An aliquot of this suspension was taken and the UV-VIS spectrum measured.
- the bonded functional agent's Lambda max peak can be observed to decrease with the free functional agent's Lambda max peak observed to appear and increase.
- the red shift is characteristic of the binding of the aryl aldehyde functionality to the silica surface.
- dilute acid hydrochloric acid as stated
- the aldehyde was released and the fragrance returned.
- the UV-VIS absorption also underwent a blue shift to return to that of the starting aldehyde.
- Such chemistry may be used in conjunction with a pharmaceutical to be released upon the change of an environmental condition to indicate/signal that the pharmaceutical material has been delivered.
- signal agent may be adsorbed onto a silica particle.
- a pharmaceutical compound may be separately adsorbed onto an alumina particle.
- the particles may be combined and jointly used within a delivery vehicle or as part of a modified drug delivery device.
- the functional agents then would be triggered upon the occurrence of separate chemical events.
- salieylaldoxime a metal sequestering agent, was also found to bind to the silica particle surface and undergo a pH triggered release.
- the structural equations and exemplary data are illustrated in the
- carrier particles and desirably nanoparticles, that is particles having sizes of less than about 1 micron in size, more desirably between about 5 nm and 500 nm in size, and even more desirably, between about 10 nm - 200 nm in size
- carrier particles can be applied to a topical bandage by various application methods.
- the application methods may include a gel, a water suspension, a dry coating or a powder placed between the layers of the bandage if the particles are included in a vehicle for ease of application.
- the bandage can then be dried, if appropriate, whereby the charges of the particles would maintain them in close association with the bandage substrate.
- the bound pharmaceutical or nutritional chemistry could be used with or without triggerable release.
- some of the bound chemistry in a multiple chemistry particle system could be triggerably releasable, while other bound chemistry could be intentionally retained on the carrier particles. In this fashion, the bound chemistry could perform its advantageous function while still being attached to the carrier particles, for ease of removal or to lower the potential toxicity of the functional agent/compound.
- tetracycline could function as an antibiotic while still being bound on a particle. This could allow the antibiotic to function in the stomach and intestines without crossing over into the bloodstream of a patient (because of the size of the particle). This control of the antibiotic release could assist with lowering the risk of sensitization of patients who are allergic to such medications.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Ceramic Engineering (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Ink Jet (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05005954A MXPA05005954A (en) | 2002-12-20 | 2003-12-11 | Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof. |
EP03814766A EP1589978A2 (en) | 2002-12-20 | 2003-12-11 | Delivery system for functional compounds |
AU2003297051A AU2003297051A1 (en) | 2002-12-20 | 2003-12-11 | Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof |
JP2005508584A JP2006518773A (en) | 2002-12-20 | 2003-12-11 | Compound comprising alumina and a compound confined to the alumina surface, system and method for supplying the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/325,474 | 2002-12-20 | ||
US10/325,474 US7666410B2 (en) | 2002-12-20 | 2002-12-20 | Delivery system for functional compounds |
US10/731,256 | 2003-12-09 | ||
US10/731,256 US20040142041A1 (en) | 2002-12-20 | 2003-12-09 | Triggerable delivery system for pharmaceutical and nutritional compounds and methods of utilizing same |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004060378A2 true WO2004060378A2 (en) | 2004-07-22 |
WO2004060378A3 WO2004060378A3 (en) | 2004-11-25 |
WO2004060378A8 WO2004060378A8 (en) | 2005-04-28 |
Family
ID=32716853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/039737 WO2004060378A2 (en) | 2002-12-20 | 2003-12-11 | Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1589978A2 (en) |
JP (1) | JP2006518773A (en) |
KR (1) | KR101012584B1 (en) |
AU (1) | AU2003297051A1 (en) |
MX (1) | MXPA05005954A (en) |
TW (1) | TWI287034B (en) |
WO (1) | WO2004060378A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666410B2 (en) | 2002-12-20 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Delivery system for functional compounds |
US7678367B2 (en) | 2003-10-16 | 2010-03-16 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified particles |
US7879350B2 (en) | 2003-10-16 | 2011-02-01 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using colloidal nanoparticles |
WO2011012867A1 (en) * | 2009-07-30 | 2011-02-03 | Sisaf Ltd | A delivery system comprising a silicon-containing material |
US8168563B2 (en) | 2003-10-16 | 2012-05-01 | Kimberly-Clark Worldwide, Inc. | Metal-modified silica particles for reducing odor |
US8409618B2 (en) | 2002-12-20 | 2013-04-02 | Kimberly-Clark Worldwide, Inc. | Odor-reducing quinone compounds |
WO2014158042A1 (en) | 2013-03-27 | 2014-10-02 | Universidade Do Minho | Reactive silica nanoparticles containing immobilized dye for permanent colouration of fibres |
WO2014200377A2 (en) | 2013-06-12 | 2014-12-18 | Ecoticket, Lda | Process for obtaining nanoparticles of silica incorporating hydrophilic products or water miscible and process for their immobilization and encapsulation when applied to textile fibres |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080145268A1 (en) * | 2006-12-15 | 2008-06-19 | Martin Stephanie M | Deodorizing container that includes an anthraquinone ink |
JP6944781B2 (en) * | 2016-01-11 | 2021-10-06 | 東京インキ株式会社 | Antibacterial coating agent, antibacterial laminate, method for producing antibacterial laminate, and film or sheet using antibacterial laminate, packaging container, packaging bag, lid material |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5000746A (en) * | 1987-08-11 | 1991-03-19 | Friedrichsfeld Gmbh Keramik- Und Kunststoffwerke | Wound covering having connected discrete elements |
EP1214879A2 (en) * | 2000-12-12 | 2002-06-19 | Takasago International Corporation | Antifungal fragrance composition |
WO2003032959A1 (en) * | 2001-10-15 | 2003-04-24 | Bosch William H | Nanoparticulate compositions comprising inorganic cores |
WO2003051278A2 (en) * | 2001-07-10 | 2003-06-26 | North Carolina State University | Nanoparticle delivery vehicle |
US20030203009A1 (en) * | 2002-04-30 | 2003-10-30 | Macdonald John Gavin | Metal ion modified high surface area materials for odor removal and control |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62179456A (en) * | 1986-01-31 | 1987-08-06 | 大日本印刷株式会社 | Film for ostomy bag |
JP2754058B2 (en) * | 1989-11-13 | 1998-05-20 | 花王株式会社 | Flaky activated alumina carrier, method for producing the same, and composite pigment using the same |
US5220346A (en) * | 1992-02-03 | 1993-06-15 | Xerox Corporation | Printing processes with microwave drying |
US5871872A (en) * | 1997-05-30 | 1999-02-16 | Shipley Company, Ll.C. | Dye incorporated pigments and products made from same |
-
2003
- 2003-12-11 WO PCT/US2003/039737 patent/WO2004060378A2/en active Application Filing
- 2003-12-11 MX MXPA05005954A patent/MXPA05005954A/en active IP Right Grant
- 2003-12-11 AU AU2003297051A patent/AU2003297051A1/en not_active Abandoned
- 2003-12-11 KR KR1020057010066A patent/KR101012584B1/en not_active IP Right Cessation
- 2003-12-11 JP JP2005508584A patent/JP2006518773A/en active Pending
- 2003-12-11 EP EP03814766A patent/EP1589978A2/en not_active Withdrawn
- 2003-12-16 TW TW092135502A patent/TWI287034B/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5000746A (en) * | 1987-08-11 | 1991-03-19 | Friedrichsfeld Gmbh Keramik- Und Kunststoffwerke | Wound covering having connected discrete elements |
EP1214879A2 (en) * | 2000-12-12 | 2002-06-19 | Takasago International Corporation | Antifungal fragrance composition |
WO2003051278A2 (en) * | 2001-07-10 | 2003-06-26 | North Carolina State University | Nanoparticle delivery vehicle |
WO2003032959A1 (en) * | 2001-10-15 | 2003-04-24 | Bosch William H | Nanoparticulate compositions comprising inorganic cores |
US20030203009A1 (en) * | 2002-04-30 | 2003-10-30 | Macdonald John Gavin | Metal ion modified high surface area materials for odor removal and control |
Non-Patent Citations (1)
Title |
---|
FREY A ET AL: "Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles" 6 August 1999 (1999-08-06), VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, PAGE(S) 3007-3019 , XP004173612 ISSN: 0264-410X abstract page 3016, left-hand column, line 21 - page 3016, left-hand column, line 32 page 3016, right-hand column, line 24 - page 3016, right-hand column, line 46 page 3009, left-hand column, line 26 - page 3009, right-hand column, line 25 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666410B2 (en) | 2002-12-20 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Delivery system for functional compounds |
US8277801B2 (en) | 2002-12-20 | 2012-10-02 | Kimberly-Clark Worldwide, Inc. | Delivery system for functional compounds |
US8409618B2 (en) | 2002-12-20 | 2013-04-02 | Kimberly-Clark Worldwide, Inc. | Odor-reducing quinone compounds |
US7678367B2 (en) | 2003-10-16 | 2010-03-16 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified particles |
US7879350B2 (en) | 2003-10-16 | 2011-02-01 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using colloidal nanoparticles |
US8168563B2 (en) | 2003-10-16 | 2012-05-01 | Kimberly-Clark Worldwide, Inc. | Metal-modified silica particles for reducing odor |
WO2011012867A1 (en) * | 2009-07-30 | 2011-02-03 | Sisaf Ltd | A delivery system comprising a silicon-containing material |
AU2010277355B2 (en) * | 2009-07-30 | 2014-12-04 | Sisaf Ltd | A delivery system comprising a silicon-containing material |
AU2010277355C1 (en) * | 2009-07-30 | 2015-06-04 | Sisaf Ltd | A delivery system comprising a silicon-containing material |
US9132083B2 (en) | 2009-07-30 | 2015-09-15 | Sisaf Ltd. | Delivery system comprising a silicon-containing material |
WO2014158042A1 (en) | 2013-03-27 | 2014-10-02 | Universidade Do Minho | Reactive silica nanoparticles containing immobilized dye for permanent colouration of fibres |
WO2014200377A2 (en) | 2013-06-12 | 2014-12-18 | Ecoticket, Lda | Process for obtaining nanoparticles of silica incorporating hydrophilic products or water miscible and process for their immobilization and encapsulation when applied to textile fibres |
Also Published As
Publication number | Publication date |
---|---|
TWI287034B (en) | 2007-09-21 |
KR101012584B1 (en) | 2011-02-07 |
WO2004060378A3 (en) | 2004-11-25 |
EP1589978A2 (en) | 2005-11-02 |
WO2004060378A8 (en) | 2005-04-28 |
MXPA05005954A (en) | 2005-08-18 |
KR20050085335A (en) | 2005-08-29 |
AU2003297051A1 (en) | 2004-07-29 |
TW200426197A (en) | 2004-12-01 |
JP2006518773A (en) | 2006-08-17 |
AU2003297051A8 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7666410B2 (en) | Delivery system for functional compounds | |
Xu et al. | Natural polyphenols as versatile platforms for material engineering and surface functionalization | |
US7371456B2 (en) | Nanoparticle based inks and methods of making the same | |
WO2004060378A2 (en) | Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof | |
Barka et al. | Photocatalytic degradation of indigo carmine in aqueous solution by TiO2-coated non-woven fibres | |
KR101493416B1 (en) | Water-triggered coloring or color changing indicator | |
EP1667738B1 (en) | Odor controlling article including a visual indicating device for monitoring odor adsorption | |
EP2453860B1 (en) | Multiple component materials having a color-changing composition | |
KR102329359B1 (en) | Colorant-containing microcapsules | |
WO2016022795A1 (en) | Wetness indicator with permanent colorant | |
MXPA04008035A (en) | Wetness indicator having improved colorant retention. | |
EP2900282A1 (en) | Liquid-activated formulation with surfactant | |
BR112013011393B1 (en) | homogeneous color-changing composition, multi-component material and disposable absorbent article | |
US20110015597A1 (en) | Multiple Component Materials Having A Color-Changing Composition | |
JP2003501216A (en) | Absorbent articles containing active additives and use of visual indicators in absorbent articles | |
KR101539903B1 (en) | Graphics performance in different absorbent article constructions | |
JP4111855B2 (en) | Plasma sterilization indicator and sterilization packaging material | |
JP4816907B2 (en) | Ink composition for oxygen indicator, oxygen indicator using the same, and packaging material containing oxygen indicator | |
EP1062285A2 (en) | Neonanoplasts and microemulsion technology for inks and ink jet printing | |
US20050226913A1 (en) | Article for inhibiting microbial growth in physiological fluids | |
Sahadevan et al. | Unconventional fluorescence behavior of ε-polylysine: Selective and sensitive detection of Cu2+ in real water samples, test paper strips, living cells, and anticounterfeiting applications | |
Akhlaghi et al. | Amino-Functionalized Pluronic F127 micelles as a dual drug delivery nanostructure for controlled therapeutics release | |
EP3662010A1 (en) | Protection and selective release of colorant | |
JP2003102811A (en) | Indicator for plasma sterilization and packaging material for sterilization | |
MXPA00001223A (en) | Neonanoplasts and microemulsion technology for inks and ink jet printing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/005954 Country of ref document: MX Ref document number: 1020057010066 Country of ref document: KR Ref document number: 20038A50879 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005508584 Country of ref document: JP Ref document number: 1127/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003814766 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057010066 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003814766 Country of ref document: EP |